A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Trial Profile

A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Avapritinib (Primary)
  • Indications Gastrointestinal stromal tumours; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 10 Nov 2017 According to a Blueprint Medicines media release, as off October 11, 2017, 116 patients had been treated including 76 patients with KIT-driven GIST, 39 patients with PDGFRa-driven GIST, and one patient with KIT/PDGFRa wild-type GIST in this trial.
    • 10 Nov 2017 According to a Blueprint Medicines media release, Michael Heinrich is investigator on this trial.
    • 10 Nov 2017 According to a Blueprint Medicines media release, the company has increased the enrollment target for patients previously treated with imatinib and at least one additional tyrosine kinase inhibitor (TKI) from 50 to 100 patients and added a new cohort to evaluate BLU-285 in second-line GIST.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top